Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia.
There is no current approved therapy for the ultimately lethal neuro- and cardio-degenerative disease Friedreich's ataxia (FA). Finding minimally-invasive molecular biomarkers of disease progression and drug effect could support smaller, shorter clinical trials. Since we and others have noted a...
Päätekijät: | Genki Hayashi, Gino Cortopassi |
---|---|
Aineistotyyppi: | Artikkeli |
Kieli: | English |
Julkaistu: |
Public Library of Science (PLoS)
2016-01-01
|
Sarja: | PLoS ONE |
Linkit: | http://europepmc.org/articles/PMC4831832?pdf=render |
Samankaltaisia teoksia
-
Sexual dimorphism in a mouse model of Friedreich’s ataxia with severe cardiomyopathy
Tekijä: Lili Salinas, et al.
Julkaistu: (2024-10-01) -
Potential biomarker identification for Friedreich's ataxia using overlapping gene expression patterns in patient cells and mouse dorsal root ganglion.
Tekijä: Marissa Z McMackin, et al.
Julkaistu: (2019-01-01) -
Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich's Ataxia.
Tekijä: Mittal Jasoliya, et al.
Julkaistu: (2019-01-01) -
Genetics and Friedreich Ataxia
Tekijä: J Gordon Millichap
Julkaistu: (2002-06-01) -
Genetics of Friedreich Ataxia
Tekijä: J Gordon Millichap
Julkaistu: (1997-06-01)